Prognosis for patients with CML and > 10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline
Susan Branford, David T Yeung, Wendy T Parker, Nicola D Roberts, Leanne Purins, Jodi A Braley, Haley K Altamura, Alexandra L Yeoman, Jasmina Georgievski, Bronte A Jamison, Stuart Phillis, Zoe Donaldson, Mary Leong, Linda Fletcher, John F Seymour, Andrew P Grigg, David M Ross, Timothy P Hughes
Blood | AMER SOC HEMATOLOGY | Published : 2014
This work was supported by the Australasian Leukaemia and Lymphoma Group and Novartis, including research support to S.B., T.P.H., D.T.Y., and D.M.R. D.T.Y. is supported by a scholarship from the Leukaemia Foundation of Australia and the AR Clarkson Foundation. W.T.P. is funded by a postdoctoral fellowship from the Leukaemia Foundation of Australia/Cure Cancer Australia.